Skip to main content
Premium Trial:

Request an Annual Quote

Joshua Baker, Gerald Fink, Mark Kay, Sara Cunningham


Joshua Baker will join Ingenium Research, a Cary, NC-based contract research organization, as president and CEO, the company said last week. Baker most recently served as president and CEO of PPGx, a pharmacogenomics research and development company. Previously, he was executive vice president of global operations for PPD Development. Baker holds a PhD and a master’s in statistics from Texas A&M University and a bachelor’s degree in mathematical science from the Pennsylvania State University.

Gerald Fink joined the scientific advisory board of Dyadic International of Jupiter, Fla., the company said last week. Fink is a professor of genetics at the Whitehead Institute/Massachusetts Institute of Technology.

Benitec has appointed to its scientific advisory board Mark Kay, director of the Human Gene Therapy program at Stanford University’s School of Medicine and a professor in pediatrics and genetics. The appointment follows Benitec’s acquisition of Sunnyvale, Calif.-based Avocel, which Kay cofounded. Benitec is based in Queensland, Australia. Kay also sits on the SAB of CombiMatrix.

Additionally, Sara Cunningham, also an Avocel co-founder and the company’s vice president of intellectual property and development, joins Benitec as chief operating officer. Previously, she had worked as a manager at BD Biosciences and Clontech.

Filed under

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.